206 related articles for article (PubMed ID: 33414846)
1. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
Reizine N; Vokes EE; Liu P; Truong TM; Nanda R; Fleming GF; Catenacci DVT; Pearson AT; Parsad S; Danahey K; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
Ther Adv Med Oncol; 2020; 12():1758835920974118. PubMed ID: 33414846
[TBL] [Abstract][Full Text] [Related]
2. Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing
Varughese LA; Bhupathiraju M; Hoffecker G; Terek S; Harr M; Hakonarson H; Cambareri C; Marini J; Landgraf J; Chen J; Kanter G; Lau-Min KS; Massa RC; Damjanov N; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
Front Oncol; 2022; 12():859846. PubMed ID: 35865463
[TBL] [Abstract][Full Text] [Related]
3. Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation.
Lau-Min KS; Varughese LA; Nelson MN; Cambareri C; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
BMC Cancer; 2022 Jan; 22(1):47. PubMed ID: 34996412
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study.
Fragoulakis V; Roncato R; Bignucolo A; Patrinos GP; Toffoli G; Cecchin E; Mitropoulou C
Pharmacol Res; 2023 Nov; 197():106949. PubMed ID: 37802427
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
[TBL] [Abstract][Full Text] [Related]
7. Clinical implementation of preemptive pharmacogenomics in psychiatry.
Skokou M; Karamperis K; Koufaki MI; Tsermpini EE; Pandi MT; Siamoglou S; Ferentinos P; Bartsakoulia M; Katsila T; Mitropoulou C; Patrinos GP;
EBioMedicine; 2024 Mar; 101():105009. PubMed ID: 38364700
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients.
Kim K; Magness JW; Nelson R; Baron V; Brixner DI
J Manag Care Spec Pharm; 2018 Dec; 24(12):1250-1259. PubMed ID: 30479202
[TBL] [Abstract][Full Text] [Related]
9. Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
Pasternak AL; Seda R; Lipa J; McDevitt RL; Crysler OV; Swiecicki PL; Schneider BJ; Vanderwerff B; Henry NL; Krauss JC; Sahai V; Hertz DL
Clin Pharmacol Ther; 2023 Aug; 114(2):356-361. PubMed ID: 37163252
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting.
Luczak TS; Schillo PJ; Renier CM; Waring SC; Friday BB
J Oncol Pharm Pract; 2022 Jun; 28(4):842-849. PubMed ID: 33853470
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology.
Shriver SP; Adams D; McKelvey BA; McCune JS; Miles D; Pratt VM; Ashcraft K; McLeod HL; Williams H; Fleury ME
J Clin Oncol; 2024 Apr; 42(10):1181-1192. PubMed ID: 38386947
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
14. Development and Implementation of In-House Pharmacogenomic Testing Program at a Major Academic Health System.
Mroz P; Michel S; Allen JD; Meyer T; McGonagle EJ; Carpentier R; Vecchia A; Schlichte A; Bishop JR; Dunnenberger HM; Yohe S; Thyagarajan B; Jacobson PA; Johnson SG
Front Genet; 2021; 12():712602. PubMed ID: 34745204
[TBL] [Abstract][Full Text] [Related]
15. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol.
Bielinski SJ; Olson JE; Pathak J; Weinshilboum RM; Wang L; Lyke KJ; Ryu E; Targonski PV; Van Norstrand MD; Hathcock MA; Takahashi PY; McCormick JB; Johnson KJ; Maschke KJ; Rohrer Vitek CR; Ellingson MS; Wieben ED; Farrugia G; Morrisette JA; Kruckeberg KJ; Bruflat JK; Peterson LM; Blommel JH; Skierka JM; Ferber MJ; Black JL; Baudhuin LM; Klee EW; Ross JL; Veldhuizen TL; Schultz CG; Caraballo PJ; Freimuth RR; Chute CG; Kullo IJ
Mayo Clin Proc; 2014 Jan; 89(1):25-33. PubMed ID: 24388019
[TBL] [Abstract][Full Text] [Related]
16. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
Varughese LA; Lau-Min KS; Cambareri C; Damjanov N; Massa R; Reddy N; Oyer R; Teitelbaum U; Tuteja S
Pharmacotherapy; 2020 Nov; 40(11):1108-1129. PubMed ID: 32985005
[TBL] [Abstract][Full Text] [Related]
17. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists.
Glewis S; Lingaratnam S; Krishnasamy M; H Martin J; Tie J; Alexander M; Michael M
J Oncol Pharm Pract; 2024 Jan; 30(1):30-37. PubMed ID: 37021580
[TBL] [Abstract][Full Text] [Related]
19. Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians.
Overby CL; Devine EB; Abernethy N; McCune JS; Tarczy-Hornoch P
J Biomed Inform; 2015 Jun; 55():249-59. PubMed ID: 25957826
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of medications given via nonconventional administration routes: a scoping review.
Socco S; Wake DT; Lee JC; Dunnenberger HM
Pharmacogenomics; 2022 Nov; 23(17):933-948. PubMed ID: 36326000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
